Abstracts Archive - Page 1902 of 2425 - ACR Meeting Abstracts

Abstract Number: 2264 • 2014 ACR/ARHP Annual Meeting
Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Nuclear Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To evaluate the efficacy of denosumab on bone mineral density (BMD) in long-term glucocorticoid users who have inadequate response to oral bisphosphonate treatment.Methods Patients…
Abstract Number: 2265 • 2014 ACR/ARHP Annual Meeting
Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients
Kowoon Joo¹, Won Park², Seong-Ryul Kwon³, Mie-Jin Lim³ and Kyong-Hee Jung³, ¹Inha University Hospital, Incheon, South Korea, ²Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Background/Purpose: Rheumatoid arthritis (RA) accelerates bone loss, increasing the risk of osteoporosis and osteoporotic fractures. We evaluated the effect of raloxifene and bisphosphonate on bone…
Abstract Number: 2266 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis
Kyung-Eun Lee¹, Lihui Wen¹, Dong-Jin Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose No available anti-osteoporotic medication has been shown to completely prevent declines in bone mineral density (BMD) and the resulting increased risk of fracture. The…
Abstract Number: 2267 • 2014 ACR/ARHP Annual Meeting
Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip over 8 Years of Denosumab Treatment
S. Ferrari¹, C. Libanati², C.J.F Lin², S. Adami³, J.P. Brown⁴, F. Cosman⁵, E. Czerwinski⁶, L.H. de Gregório⁷, J. Malouf⁸, J.-Y. Reginster⁹, N.S. Daizadeh², A. Wang², R.B. Wagman², E.M. Lewiecki¹⁰ and S. Cummings¹¹, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of Verona, Verona, Italy, ⁴Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, ⁵Helen Hayes Hospital, West Haverstraw, NY, ⁶Krakow Medical Center, Krakow, Poland, ⁷CCBR, Rio de Janeiro, Brazil, ⁸Universitat Autònoma de Barcelona, Barcelona, Spain, ⁹University of Liège, Liège, Belgium, ¹⁰New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹¹San Francisco Coordinating Center, CPMC Research Institute, and UCSF, San Francisco, CA
Background/Purpose: Guidelines for the treatment of chronic conditions such as hypertension and diabetes include specific biomarker targets. This differs from osteoporosis treatment guidelines, which currently…
Abstract Number: 2268 • 2014 ACR/ARHP Annual Meeting
Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Silvano Adami⁵, Henry G. Bone⁶, Tobias de Villiers⁷, Douglas P. Kiel⁸, Annie Kung⁹, Prasanna Kumar¹⁰, Sung-Kil Lim¹¹, Xu Ling¹², Kurt Lippuner¹³, Carlos Mautalen¹⁴, Toshitaka Nakamura¹⁵, Jean-Yves Reginster¹⁶, Ian R. Reid¹⁷, José Adolfo Rodríguez-Portales¹⁸, Christian Roux¹⁹, Jesus Walliser²⁰, Nelson B. Watts²¹, José R. Zanchetta²², Cristiano A.F. Zerbini²³, Andrea Rybak-Feiglin²⁴, Dosinda Cohn²⁴, Carolyn A. DaSilva²⁴, Rachid Massaad²⁵, Arthur Santora²⁴, Boyd B. Scott²⁴, Nadia Verbruggen²⁵, Albert Leung²⁶ and Antonio Lombardi²⁴, ¹Oregon Osteoporosis Center, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Department, University of Verona, Verona, Italy, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, ⁹University of Hong Kong, Pokfulam, Hong Kong, China, ¹⁰Bangalore Diabetes Centre, Bangalore, India, ¹¹Yonsei University, Seoul, South Korea, ¹²Peking Union Medical College Hospital, Beijing, China, ¹³Bern University Hospital, Bern, Switzerland, ¹⁴Centro de Osteopatías Médicas, Buenos Aires, Argentina, ¹⁵University of Occupational & Environmental Health, Fukuoaka, Japan, ¹⁶CHU-Centre Ville, Policliniques BRULL, Liege, Belgium, ¹⁷Department of Medicine, University of Auckland, Auckland, New Zealand, ¹⁸Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁹Paris Descartes University, Cochin Hospital, Paris, France, ²⁰Bone Metabolism Clinic, Hospital Angeles del Pedregal, Mexico City, Mexico, ²¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²²IDIM Instituto de Investigaciones Metabolicas, Buenos Aires, Argentina, ²³Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²⁴Merck Sharp and Dohme Corp., Rahway, NJ, ²⁵MSD Europe Inc., Brussels, Belgium, ²⁶Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. The Phase III Long-Term Odanacatib Fracture Trial…
Abstract Number: 2269 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of High Dose Infliximab in the Treatment of Uveitis in Pediatric Patients
Liza Mariel Bermudez¹, Patricia Irigoyen¹, Anca Askanase², Michael Weiss³, Joyce Hui-Yuen¹, Amy J. Starr², Lisa F. Imundo⁴, Andrew H. Eichenfield² and Josephine Isgro¹, ¹Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Division of Ophthalmology Uveitis Service College of Physician And Surgeons of Columbia University, New York, NY, ⁴Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY
Background/Purpose Chronic uveitis, an inflammatory eye disease, is a leading causes of childhood blindness and often has a chronic recurrent course. This study reviews the efficacy and safety of high…
Abstract Number: 2270 • 2014 ACR/ARHP Annual Meeting
Changes in Cerebral Blood Flow Velocity in Patients with Familial Mediterranean Fever
Gozde Yildirim Cetin¹, Uygar Utku², Nurhan Atilla³, Kadir Gisi⁴ and Mehmet Sayarlioglu⁵, ¹Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, ²Neurology, Kahramanmaras Sutcu Imam University, Medical Faculty, Kahramanmaras, Turkey, ³Chest Diseases, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey, ⁴Gastroenterology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey, ⁵Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey
Background/Purpose Familial Mediterranean fever (FMF) is a hereditary and an auto-inflammatory disease predominantly characterized by repeated attacks of fever, abdominal pain, pleuritic chest pain, arthritis…
Abstract Number: 2271 • 2014 ACR/ARHP Annual Meeting
Symptom and Treatment Characteristics of Juvenile Primary Fibromyalgia Syndrome: Are Males and Females Created Equal?
Jennifer E. Weiss¹, Kenneth N. Schikler², Alexis Boneparth³, Cara Hoffart⁴, Mark Connelly⁵ and The CARRA Registry Investigators⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, ³Pediatric Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Rheumatology and Integrative Pain Management, Children's Mercy Hospital, Kansas City, MO, ⁵Children's Mercy Hospital, Kansas City, MO, ⁶Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose Children and adolescents with persistent widespread musculoskeletal pain frequently present to pediatric rheumatologists for evaluation. Limited data are available on the characteristics and treatments…
Abstract Number: 2231 • 2014 ACR/ARHP Annual Meeting
Combined Chondroitin Sulfate and Glucosamine Is Comparable to Celecoxib for Painful Knee Osteoarthritis. Results from a Multicenter, Randomized, Double-Blind, PHASE IV NON-Inferiority TRIAL
Marc Hochberg¹, Johanne Martel-Pelletier², Jordi Monfort³, Ingrid Moller⁴, Juan Ramon Castillo⁵, Nigel K. Arden^6,7,8, Francis Berenbaum^9,10, Jean-Pierre Pelletier¹¹, Francisco J. Blanco¹², Philip G. Conaghan¹³, Yves Henrotin^14,15, Thomas Pap¹⁶, Pascal Richette^17,18,19, Allen Sawitzke²⁰, Patrick du Souich²¹ and Moves Investigation Group²², ¹University of Maryland School of Medicine, Baltimore, MD, ²Osteoarthritis Research Unit CR-CHUM, Notre-Dame Hospital 1560 Sherbrooke St East, Montreal, QC, Canada, ³Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, ⁴Instituto Poal, Barcelona, Spain, ⁵Head of Clinical Pharmacology Unit Hospital Universitario Virgen del Rocío, Sevilla, Spain;, Sevilla, Spain, ⁶NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁷Arthritis Research UK (ARUK), Center for Sports, Exercise and Osteoarthritis, University of Oxford, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁹Sorbonne University, INSERM UMR S938, UPMC, University of Paris 06, DHU i2B, Paris, France, ¹⁰Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ¹¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada, ¹²Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ¹³University of Leeds, Leeds, United Kingdom, ¹⁴Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium, ¹⁵Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology, CHU Sart-Tilman, Liege, Belgium, ¹⁶Institute of Experimental Muskuloskeletal Medicine University Hospital Münster, Münster, Germany, ¹⁷Université Paris Diderot, UFR médicale, Paris, France, ¹⁸INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ¹⁹2 Rue Ambroise Pare, Hopital Lariboisiere, Paris, France, ²⁰Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²¹Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada, ²²Spain, Germany, France and Poland, Barcelona, Spain
Background/Purpose The Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) compared efficacy and safety of Chondroitin sulfate (CS) and Glucosamine Hydrochloride (GH) with that of Celecoxib…
Abstract Number: 2232 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis
Vishvas Garg¹, Dennis Raisch², Ning Yan Gu³, Matthew E Borrego³ and Daniel O. Clegg⁴, ¹College of Pharmacy, University of New Mexico (at the time of research), Grayslake, IL, ²College of Pharmacy, University of New Mexico, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM, ⁴Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT
Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US population aged ≥26, causing significant burden-of-illness. We compared the cost-effectiveness of conventional medicines such as non-steroidal…
Abstract Number: 2233 • 2014 ACR/ARHP Annual Meeting
A PHASE 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC-10004) in Subjects with Erosive Hand Osteoarthritis
Juergen Rech¹, Francesca Faustini¹, Axel J. Hueber¹, Wolfgang Ochs², Wolfgang Spieler³, Herbert Kellner⁴, Ulf Muller-Ladner⁵, Mathias Grünke⁶, Matthias Schneider⁷ and Georg Schett⁸, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatologist in private practice, Bayreuth, Germany, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ⁵Internal Medicine/Rheumatology, Univ Giessen/Kerckhoff-Clinic, Bad Nauheim, Germany, ⁶Division of Rheumatology, University of Munich, Munich, Germany, ⁷Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose We report on a phase II, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study in subjects with erosive hand osteoarthritis. Subjects must have had…
Abstract Number: 2234 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Liposome Intra-Articular Injection in Moderate Knee Osteoarthritis. a Prospective Randomized Double-Blinded Study
Leonid Kandel¹, Yaniv Dolev², Rachel Shimonov¹, Gurion Rivkin¹, Meir Liebergall¹, Yoav Mattan¹ and Xavier Chevalier³, ¹Orthopedic Surgery Department, Hadassah Medical Center, Jerusalem, Israel, ²Moebius Medical Ltd., Tel Aviv, Israel, ³Department of Rheumatology Hopital Henri Mondor, Créteil, France
Background/Purpose: Bio-lubrication is a prerequisite for proper joint mobility and is crucial for prevention of degradative changes of the joint. Phospholipids are components of the…
Abstract Number: 2235 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities
Jeffrey N. Katz¹, Savannah Smith², Jamie E. Collins³, Joanne M. Jordan⁴, David J. Hunter⁵, Edward H. Yelin⁶, Lisa Suter⁷, A. David Paltiel⁸ and Elena Losina³, ¹Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ²Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁷Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT, ⁸Yale School of Public Health, New Haven, CT
Background/Purpose: Because older patients with osteoarthritis (OA) and multiple comorbidities face high risk of toxicity from nonselective non-steroidal antiinflammatory drugs (NSAIDs) and Cox-2 inhibitors, opiates…
Abstract Number: 2236 • 2014 ACR/ARHP Annual Meeting
Plant–Derived Products Are Effective for Treatment of OA Pain and Safer Than Other Active Therapies
Laura Laslett, Xingzhong Jin and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, HOBART, Australia
Background/Purpose: Osteoarthritis (OA) is a leading cause of chronic disability. There are no approved treatments for modifying the disease course, therefore disease management consists of…
Abstract Number: 2237 • 2014 ACR/ARHP Annual Meeting
Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients
Susanne X. Wang¹, Jeroen Medema¹, Matthew Kosloski¹, Wei Liu¹, Mary Saltarelli¹ and Morten Asser Karsdal², ¹AbbVie Inc., North Chicago, IL, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) may comprise multiple phenotypes, one of which is inflammation-driven OA. Consequently, a selected subpopulation of OA patients may benefit from optimally targeted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].